Estrogen Receptor Agonist Market Analysis

  • Report ID: 4982
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Estrogen Receptor Agonist Market Analysis

Route of Administration (Oral, Parental)

Estrogen receptor agonist market from the oral segment is anticipated to garner the highest revenue by the end of 2036. This segment growth is estimated to boost on account of its cost efficiency. Since parenteral drugs must be sterile and isotonic, the oral pharmaceuticals on the market are less expensive, which results in financial savings for the patient. Moreover, oral medication gets absorbed at a faster rate. Hence, they are most preferred.

Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)

The hospital pharmacies segment in the estrogen receptor agonist market is set to have noteworthy growth over the forecast period. Most of estrogen receptor agonist drugs are prescribed by the doctors. Hence, the pharmacies attached to the hospitals are estimated to satisfy the growing demand for this medication.

Our in-depth analysis of the global market includes the following segments:

 

    Product Type

  • Endogenous
  • Synthetic
  • Natural

    Indication Type

  • Cancer
  • Neurodegenerative Diseases
  • Inflammatory Diseases
  • Cardiovascular Diseases

 

    Route of Administration

  • Oral
  • Parental

 

 

    Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4982
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of estrogen receptor agonist is evaluated at USD 4.59 Billion.

The estrogen receptor agonist market size was valued at USD 4.3 Billion in 2023 and is expected to exceed USD 11.01 Billion by the end of 2036, expanding at over 7.5% CAGR during the forecast period i.e., between 2024-2036. The major factors driving the growth of the market are the growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

Asia Pacific industry is set to have the highest growth by 2036, backed by growing geriatric population in this region.

AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, Merck KGaA, Vivesto AB, Oncternal Therapeutics, Pfizer Inc., Tocris Bioscience, Tokyo Chemical Industry Co., Ltd
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample